本研究選擇世界各國在二十一世紀中競相投入資源發展的生物科技產業為研究重心，透過回顧目前該產業的現況、融資特色與智財權保護等相關研究，接著再加以融入傳統融資理論與融資決策影響創新相關的文獻，探討生物科技產業在不同條件與階段下合適的企業融資策略。
生技產業有別於一般產業，客觀產業條件存在高度營業風險、長時間資源投入、長期間的財務回報等營業特性。本研究選取臺灣2011年到2015年總共395個公開發行的生技企業樣本其中的若干財務指標，並且將其區分為三大子產業，透過實證研究分析產業融資概況、財務結構及其影響因素，最後得出結論：臺灣股票市場對於生技股票普遍給予較高的估值，臺灣生技產業政策的鼓勵讓許多尚未獲利的生技企業得以運用股票市場籌資。其次是臺灣生技企業的負債比率與無形資產占淨值比、淨值成長比、營業收入、稅率與固定資產呈現正比；與研發費用、資產報酬率與市場價值呈現反比。臺灣生技業的行業特性包含高度無形資產累積、智慧產權高度保護、營業風險大以及研發週期和財務回報回收期限長等特性，造成其融資策略上有屬於自己的產業特色，相較其他傳統產業有所不同。

This paper select the biotech industry as the topic, which is seemed as a super-star industry in the 21st century. By reviewing the current status of this industry, financing characteristics and the protection of intellectual property rights in biotech industry, traditional capital structure theory and the researches about the impact between financing strategy and corporation innovation, this paper try to find the optimal corporate financing strategies in different conditions and stages of the biotech companies.
Biotechnology industry is different from the general industry with high business risk, long time and large investment and long-term financial return. This study selected 395 publicly-listed biotech samples in Taiwan from 2011 to 2015 and divided them into three sub-industries. Then this study analyzed the financing profiles and capital structure of these samples. Finally, it is concluded that Taiwan stock market generally gives high valuation for biotech stocks. And the encouragement of Taiwan's biotechnology industry policy allows many unprofitable biotechnology companies to raise funds from the stock market. Secondly, In Taiwanese biotech enterprises the intangible assets proportion in net value, net value growth ratio, operating income, fixed assets and tax rate are direct proportional to the debt ratio. R & D expenses, ROA and market value are inversely proportional to the debt ratio. The industry characteristics of Taiwan's biotechnology industry include high intangible asset accumulation, high intellectual property rights protection, large business risk, long development cycle and long financial return period. As a result, its financing strategy has its own industrial characteristics compared with other traditional industries.

中文部分
1.俞海琴，陳慧娟，1999，我國上市公司成長、杠杆與托賓Q關聯之研究，風險管理學報，Vol.1 NO.1。
2.許楨屏，2014，高風險科技產業之融資政策與績效：臺灣地區實證研究，交通大學科技管理研究所博士論文。
3.陳昌禮，2004，生物科技產業價值創造之效率研究，中國文化大學經濟研究所碩士論文。
4.楊幼瑤，2014，基於生命周期的生物製藥企業之融資策略研究，廈門大學工商管理碩士論文。
5.楊軍敏，2006，科技型企業融資行為與資本結構研究，上海復旦大學管理科學與工程學位博士論文。
6.劉維琪、李怡宗. (1993b). 融資順位理論之調查研究. 管理評論, 119-144.
7.劉維琪、劉玉珍. (1989). 融資順位理論之發展與實證. 管理評論, 7-22.
8.經濟部工業局，2016，2016臺灣生技產業白皮書，經濟部工業局。
9.歐育成，1998，公司價值和系統風險關係之實證研究---以台灣上市公司為例，國立中山大學企業管理學系研究所碩士論文
10.歐朝銓，尚未出版，高新技術產業融資與資本結構研究—臺灣地區生物技術產業實證分析，南開大學金融學位博士論文。
11.鄭師安，2010，台灣生技企業特殊籌資工具之探索性研究，國立政治大學商管專業學院碩士論文。
12.謝劍平，2016，財務管理原理 七版，智勝文化。
13.謝劍平，2015，財務報表分析 四版，智勝文化。
14.謝劍平，2014，國際財務管理：跨國企業之價值創造 二版，智勝文化。
英文部分
1.Bah, R., and Dumontier, P. 2001. “R&D intensity and corporate financial policy: Some international evidence.” Journal of Business Finance & Accounting, June 671-692.
2.De Angelo, Harry, and Masulis, Ronald W. 1980. “Optimal capital structure under corporate and personal taxation.” Journal of Financial Economics, Vol.8 3-29.
3.D Galai, and RW. Masulis. 1976. “The option pricing model and the risk factor of stock”Journal of Financial economics, Vol. 3, Issues 1–2, 53–81
4.Jenson, Michael C., and Meckling William H. 1976. “Theory of the firm; managerial behavior, agency costs and ownership structure.” Journal of Financial Economics, Vol. 3, 305-360
5.Myers, Stewart C.1977.” Determinants of corporate borrowing.” Journal of Financial Economics. Vol 5, 147-175.
6.Nance, D. R., Smith, C. W., & Smithson, C. W. 1993, “On the determinants of corporate hedging.” The Journal of Finance, Vol. 48(1), 267-284.
7.Rajan, R. G., and Zingales, L. 1998, “Which capitalism? Lessons form the east Asian crisis.” Journal of Applied Corporate Finance, Vol. 11(3), 40-48
8.Smith, C. W., and Stulz, R. M. 1985, “The determinants of firms' hedging policies.” Journal of financial and quantitative analysis, Vol, 20(04), 391-405.
9.Smith, C. W., & Watts, R. L. 1992, “The investment opportunity set and corporate financing, dividend, and compensation policies.” Journal of financial Economics, Vol. 32(3), 263-292.
10.Sudipto Bhattacharya and Jay R. Ritter.1983.” Innovation and Communication: Signaling with Partial Disclosure” Review of Economic Studies Vol.50, 331-346.
11.Williamson, Oliver, 1988, “Corporate finance and corporate governance.” Journal of Finance, Vol. 43,567-591.
網站資料部分
1.基因泰克公司網站
https://www.gene.com/
2.經濟部工業局，「受託提供係屬科技事業暨產品或技術開發成功且具市場性意見」http://www.moeaidb.gov.tw/external/ctlr?PRO=application.ApplicationView&id=193
3.臺灣證券櫃檯買賣中心，科技事業及文創事業上櫃專區http://www.tpex.org.tw/web/link/tech_ipo.php?l=zh-tw
4.世界衛生組織
http://www.who.int/en/